UC

PJSC RusHydro: RusHydro Group announces 9M 2021 IFRS results

Thursday, November 25, 2021 - 12:06pm

In 9M 2021, the Group's net profit decreased by 13.3% to RUB 52,443 mn following absence of significant revaluations of the forward contract on the company's shares which was accounted for in 9M 2020.

Key Points: 
  • In 9M 2021, the Group's net profit decreased by 13.3% to RUB 52,443 mn following absence of significant revaluations of the forward contract on the company's shares which was accounted for in 9M 2020.
  • RusHydro Group began construction of 23.4 MW Cherekskaya small HPP (earlier Psygansu small HPP) in Kabardino-Balkarian Republic.
  • *****The Boguchanskaya hydropower plant is part of the Boguchanskiy Energy and Metals Complex (BEMO), a joint venture (JV) between RusHydro and UC RUSAL, and is not part of RusHydro Group.
  • RusHydro Group is the leading producer of renewable energy in Russia with over 400 generating facilities.

Operator Strategies for Large Unified Communications Enterprises, 2021 Report: Strong Partnerships and the Effective Use of Network Assets Will Be Crucial to Operators' Success - ResearchAndMarkets.com

Wednesday, November 24, 2021 - 5:47pm

The "Unified Communications: Operator Strategies for Large Enterprises" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Unified Communications: Operator Strategies for Large Enterprises" report has been added to ResearchAndMarkets.com's offering.
  • The large enterprise unified communications (UC) market is forecast to be worth USD15 billion in 2025 and represents an important revenue growth opportunity for operators.
  • The report draws on insight from more than 20 interviews with operators and UC vendors.
  • An overview of the additional services that operators should integrate with their core UC portfolios.

Europe Mobile Broadband Markets, Trends and Opportunities Report 2021-2026 - ResearchAndMarkets.com

Tuesday, November 23, 2021 - 3:17pm

The "Europe Mobile Broadband Market Trends and Opportunities to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Mobile Broadband Market Trends and Opportunities to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The report provides an executive-level overview of the mobile broadband market in Europe.
  • Governments and regulators in Europe are working in tandem to drive and develop mobile broadband infrastructure and adoption, especially in regards to 5G - with major high-speed broadband coverage targets set across Europe.
  • Section 3: Mobile Broadband Subscription Trends: Provides analysis, historical figures, and forecasts of mobile broadband subscriptions and usage trends in the region as well as their growth drivers.

Cruz Foam Closes $2.5M Seed Funding Round to Accelerate Circular Protective Packaging Solutions

Tuesday, November 23, 2021 - 1:00pm

"Cruz Foam is taking on plastic pollution at the root -- by inventing a versatile, earth-compatible foam with disruptive economics, requiring no technical recycling to return to the nutrient cycle," said Tom Chi, Founding Partner, At One Ventures. "We believe this approach will help set the standard for the future of packaging and sustainable materials."

Key Points: 
  • Cruz Foam intends to use the funds to continue scaling its operations to support the commercial launch of pioneering Fortune 500 companies replacing their traditional petroleum-based protective packaging with certified compostable Cruz Foam solutions.
  • Cruz Foam is also announcing the addition of several high-profile advisors who bring invaluable expertise to the scaling and execution of the company's strategic plans.
  • Cruz Foam is a unique, bio-benign foam material used in protective packaging that matches the technical strength, flexibility, and protective qualities of petroleum-based foams (commonly known as Styrofoam) and at a similar price.
  • Cruz Foam is a bio-material technology company that produces ASTM certified compostable, protective packaging foam, and other eco-friendly solutions that offer a sustainable alternative to petroleum-based products.

Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis

Tuesday, November 23, 2021 - 11:59am

The most common adverse reactions leading to discontinuation were related to liver enzyme elevations (1.1%) in the MS clinical studies.

Key Points: 
  • The most common adverse reactions leading to discontinuation were related to liver enzyme elevations (1.1%) in the MS clinical studies.
  • Bristol Myers Squibb thanks the patients and investigators involved in the True North clinical trial.
  • Bristol Myers Squibb is continuing to evaluate Zeposia in an open-label extension trial, which is ongoing and designed to assess the longer-term profile of Zeposia for the treatment of moderately to severely active UC.
  • The company is also investigating Zeposia for the treatment of moderately to severely active Crohns disease in the ongoing Phase 3 YELLOWSTONE clinical trial program.

Connect Biopharma Expands Executive Leadership Team with Hire of Chief Financial Officer

Monday, November 22, 2021 - 1:00pm

Mr. Chan will report to Dr. Zheng Wei, Co-Founder & CEO, and succeed Eric Hall who served as Interim Chief Financial Officer.

Key Points: 
  • Mr. Chan will report to Dr. Zheng Wei, Co-Founder & CEO, and succeed Eric Hall who served as Interim Chief Financial Officer.
  • We are delighted to welcome Steven to Connects Executive team at this exciting time for the Company.
  • Mr. Chan joins Connect from Delphon Industries LLC, a global materials manufacturer for the semiconductor, photonics, electronics and medical industries based in Hayward, California where he served as Chief Financial Officer and led its finance, human resources and legal functions.
  • Connect Biopharma cautions that statements included in this press release that are not a description of historical facts are forward-looking statements.

Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis

Friday, November 19, 2021 - 1:00pm

All enrolled patients are expected to participate in a follow-up phase of 4 weeks following the end of the maintenance phase ( NCT04700449 ).

Key Points: 
  • All enrolled patients are expected to participate in a follow-up phase of 4 weeks following the end of the maintenance phase ( NCT04700449 ).
  • We are pleased to complete the enrollment of the CBP-307 global phase 2 trial in patients with moderate-to-severe UC, our lead clinical program for our oral S1P1 modulator, said Zheng Wei, PhD, Co-Founder and CEO of Connect Biopharma.
  • Ulcerative colitis (UC) is a common form of inflammatory bowel disease (IBD) that causes chronic inflammation of the large intestine.
  • Connect Biopharma cautions that statements included in this press release that are not a description of historical facts are forward-looking statements.

Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis

Thursday, November 18, 2021 - 9:02pm

SAN DIEGO and TAICANG, SUZHOU, China , Nov. 18, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today reported positive topline results from the global Phase 2 clinical trial of CBP-201 administered subcutaneously (SC) to adult patients with moderate-to-severe atopic dermatitis (AD) (NCT04444752).

Key Points: 
  • Finally, there were a low reported incidence of injection site reactions (1.8%) and conjunctivitis (3.5%) in patients receiving CBP-201.
  • We are very pleased to have successfully completed this trial on schedule despite the challenges of the COVID-19 pandemic.
  • The Company intends to hold a conference call to discuss the detailed trial results from this global Phase 2 clinical trial by the end of January 2022, following the completion of further analyses.
  • Connect Biopharma cautions that statements included in this press release that are not a description of historical facts are forward-looking statements.

Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update

Wednesday, November 17, 2021 - 9:11pm

ENCINITAS, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, today announced financial results for the quarter ended September 30, 2021.

Key Points: 
  • The aggregate net proceeds from the offering were approximately $158.8 million after deducting underwriting discounts, commissions and offering expenses.
  • The presentation of the balances and amounts below for the third quarter 2021 reflect the financial results of Ventyx Biosciences, Inc. and its two wholly-owned subsidiaries, Oppilan Pharma, Ltd. and Zomagen Biosciences, Ltd., on a consolidated basis, as of the acquisition date of February 26, 2021.
  • The presentation of the balances and amounts below for the third quarter 2020 reflect the financial results of Ventyx Biosciences, Inc. on a standalone basis.
  • The inclusion of forward-looking statements should not be regarded as a representation by Ventyx that any of its plans will be achieved.

Mobile Video Devices (MVD) and ScreenBeam Forge Distribution Partnership for Wireless Presentation and Collaboration Innovations

Monday, November 22, 2021 - 2:00pm

ScreenBeam's award-winning wireless collaboration and content sharing solutions transform meeting and learning spaces with OS-native wireless display and agnostic support for video conferencing platforms.

Key Points: 
  • ScreenBeam's award-winning wireless collaboration and content sharing solutions transform meeting and learning spaces with OS-native wireless display and agnostic support for video conferencing platforms.
  • The flagship ScreenBeam 1100 Plus is a flexible, high-performing wireless presentation and Unified Communications (UC) platform enabling hybrid meeting spaces.
  • "We are thrilled to have Mobile Video Devices join our distribution network," said Mike Ehlenberger, ScreenBeam vice president and general manager.
  • About Mobile Video Devices Mobile Video Devices Inc. (MVD) provides distribution services and manufacturer representation in the Americas with a focus on technologies for live streaming, video conferencing, collaboration, networking, and video production.